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Interferons are cellular  glycoproteins that inhibit viral  replication and that 
may be involved in the defensive response of  an animal to virus infection.  Virus 
infection  of  cells  induces the synthesis and release of  interferons,  which render 
uninfected cells  resistant  to virus infection.  Interferon can be induced by agents 
other than viruses, such as micro-organisms (1),  substances of  microbial origin 
(2), and  synthetic  polymers  (3). Although  interferon is not specific for a 
particular virus, it displays a characteristic  cell  specificity,  being more active 
on homologous than on heterologous cells.  Interferons not only display anti- 
viral  activity,  but also  have been shown to affect  various cellular  mechanisms 
that are not directly  related to viral  replication.  Interferons inhibit  cell  growth 
(4),  facilitate  or suppress interferon i~duction (priming and blocking effects)  (5, 
6), and increase the susceptibility  of cells to the toxicity of double-stranded 
RNAs  (7).  Moreover, they affect  several immunological functions: interferons 
inhibit antibody  formation  in vivo  and  in vitro (8, 9), and  enhance  the 
phagocytic activity  of  macrophages (10),  the cytotoxicity  of  lymphocytes (11-13), 
and IgE-mediated histamine release from basophils (14). 
Exposure of  lymphocytes to  viruses induces the  release  of  interferon  molecules 
that can be distinguished  immunologically  from the interferon produced by 
other cell  types (15).  The synthesis of  interferon from lymphocytes can also  be 
induced by immune stimulation (bacterial  [16]  and viral  antigens [17-19],  allo- 
antigens [20]),  anti-lymphocyte sera (21),  and mitogenic lectins  (22). 
We have recently described that viral inhibitors are released in the super- 
nates of mixed cultures of lymphocytes  and certain tumor-derived  or virus- 
transformed cell  cultures (23).  In the present study we identify  these inhibitors 
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as  interferons  and  characterize  some  of  their  anti-viral  and  anti-cellular 
activities.  Moreover  we  identify  the  producer  cells  in  the  human  peripheral 
blood as Fc-receptor bearing lymphocytes that have no surface immunoglobulins 
and that do not form rosettes with sheep erythrocytes. 
Materials and Methods 
Reagents.  The reagents used in these studies and their sources are as follows: cycloheximide, 
2-aminoethylisothio-uronium bromide hydrobromide  (AET), 1 and trypsin crystallized two times 
from bovine pancreas  (3.4.4.4)  from Sigma Chemical Co.,  (St.  Louis, Mo.); actinomycin D from 
Calbiochem (San Diego, Calif.). 
Cell Lines and  Virus.  The origin of and  reference for the cell lines used in this study  are 
summarized in Tables I and II. Most of the simian virus 40 (SV40)-  and adenovirus 5-transformed 
cell lines were originated in our laboratories. 
The 73-T strain of Newcastle disease virus (NDV)  (allantoic fluid, 3.3  x  109 plaque-forming 
units (PFU)/ml on L929 cells), the Indiana strain of vesicular stomatitis virus (VSV, 3 ×  l0  s PFU/ 
ml on  L-F2 cells) and  encephalomyocarditis  virus  (EMC,  4  ×  l0 s PFU/ml on  F-F~  cells) were 
originally obtained from T. J. Wiktor (Wistar Institute).  Vaccinia virus (Lister strain),  provided 
by M. Herlyn (Wistar Institute), was originally obtained from Wyeth Laboratory, (106 TCID50/ml 
on WI38 cells). The Hong Kong/107/68  (H3N2)  strain  of influenza A  virus (allantoic fluid,  850 
hemagglutination units-ml) was obtained from W. Gerhard (Wistar Institute). 
Human Lymphocyte Separation.  Lymphocytes were obtained from heparinized human periph- 
eral  blood  by  centrifugation  on  a  Ficoll-Hypaque gradient  (31).  The  lymphocyte  suspensions 
obtained was contaminated by 5-30% monocytes as identified by nonspecific acid esterase staining 
(acid a-naphthyl acetate esterase, ANAE) (32) and was further depleted of adherent cells by two 
1-h incubations on glass Petri dishes at 37°C. 
Further cell fractionation was obtained by separation of nylon fiber-adherent cells (33). 
Cells bearing surface immunoglobulins or Fc-receptors were removed by passing the lympho- 
cyte population through a  Sepharose IgG-anti-IgG column.  Cyanogen bromide-activated Sepha- 
rose 6B  (Pharmacia,  Uppsala,  Sweden)  was conjugated  with  normal  human  IgG  (purified  by 
DEAE chromatography,  10 mg/ml of gel), and columns containing 6 ml gel were prepared.  20 mg 
of IgG from a polyvalent rabbit anti-human IgG serum was run on the column, which was eluted 
several  times before  l0  s lymphocytes  in  RPMI  1640  medium  (1%  FBS) were  added  to  it  and 
incubated  30  min  at  4°C.  The  nonadherent  cells  were  eluted  from  the  column  with  ice-cold 
medium. Columns without anti-IgG serum were used as controls. 
Cells forming rosettes with AET-treated sheep erythrocytes were separated from non-rosette- 
forming cells by the method of Pellegrino and Ferrone (34). 
Mixed  Cultures.  Tumor-derived,  virus-transformed,  and  fibroblast  cell  monolayers  were 
grown  in  16-mm  wells  (Disposo  Trays  FB16-24TC,  Linbro  Scientific,  Inc.  Div.  of Flow Lab., 
Hamden,  Conn.).  Lymphocytes depleted of glass adherent  cells were resuspended  at  107/ml  in 
RPMI-1640 medium supplemented with 10% fetal bovine serum (RPMI-FBS, Flow Laboratories, 
Inc., Rockville, Md.)  and  1 ml was added to each well. The mixed cultures were incubated  for 
24  h  at  37°C  in  a  humidified  5%  CO2:95%  air  atmosphere,  then  the  supernate  was  collected, 
centrifuged at 1,000 g  for 30 min, and stored at  -80°C until tested. 
Interferon  Tests.  For testing human  interferon,  monolayers of fetal  skin  fibroblasts  (FS2) 
were grown in the wells of microtiter plates  (3040,  BioQuest,  BBL & Falcon Products,  Becton, 
Dickinson  &  Co.,  Cockeysville, Md.).  The  medium  was  removed  from  the  wells,  and  0.1-ml 
samples of serial dilutions of the supernates to be tested were added. After an 18-h incubation, the 
supernates were removed and 0.2 ml of VSV (50,000 PFU) was added to each well. The anti-viral 
activity was measured by inhibition of the cytopathic effect of VSV. Anti-viral units are expressed 
1  Abbreviations  used in this paper: AET, 2-aminoethylisothio-uronium bromide hydrobromide; 
ANAE, acid alphanaphthyl  acetate esterase; EBV, Epstein-Barr virus; EMC, encephalomyocar- 
ditis virus; FBS, fetal bovine serum; HAU, hemagglutination units; MOI, multiplicity of infection; 
NDV,  Newcastle  disease  virus;  PBS,  phosphate-buffered  saline;  PFU,  plaque-forming  unit; 
RDMC, rhabdomyosarcoma cell line; SV40, simian virus 40; TCID~o, tissue culture infectious dose 
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as the  reciprocal  of the  highest  dilution  inhibiting  50% of the cytopathic  effect.  Each  assay 
included a standard interferon preparation (NIH human Reference Interferon G-023-901-527 with 
a titer of 20,000 U).  1 anti-viral U in our testing procedure  is equivalent to approximately 1 
reference  U of the NIH interferon. 
Mouse interferon was similarly measured on monolayers of murine L-F2 cells, by using EMC 
(50,000 PFU/well) as the challenge  virus (35). Assays were standardized against an NIH mouse 
interferon reference standard.  1 anti-viral U in this testing procedure  cells is equal to 1 U of 
reference standard. 
Leucine, Uridine, and Thymidine Uptake.  104 trypsinized cells  in 0.1  ml RPMI-FBS were 
added  to flat bottom wells  of microtiter plates  (3040, Falcon),  and 0.1  ml of dilutions of the 
supernates to be tested were added to triplicate wells. The cells were incubated  for 18 h at 37°C, 
then 2 ~Ci of [3H]labeled precursors (New England Nuclear Corp., Boston, Mass.) were added to 
each well. The cells were incubated for another 6 h, then the medium was removed,  0.2 ml of 
trypsin (0.25%) was added, and the cells were collected on to glass fiber filters (GF/B, Whatman, 
Inc., Clifton, N. J.) by means of a semi-automatic collector (O. Hiller, Madison, Wis.). Radioactiv- 
ity was assessed by liquid scintillation  spectrometry. [3H]thymidine uptake inhibitory units are 
defined at the reciprocal of the dilution inhibiting 50% [3H]thymidine uptake in rhabdomyosar- 
coma (RDMC) cells. 
Results 
Anti-Viral Activity in  the Supernates  of Mixed Cultures.  The  results  ob- 
tained by testing for presence of anti-viral activity in the supernates of mixed 
cultures of human lymphocytes with cells obtained from fibroblast, virus-trans- 
formed, tumor-derived,  and lymphoid cell lines are summarized in Table I. No 
anti-viral activity was usually observed in the supernates from human lympho- 
cytes cultured  alone.  None of the  13  human  fibroblast cultures tested induced 
anti-viral activity when mixed with human  lymphocytes, whereas 13 out of 21 
tumor-derived  cell  lines  were  inductive.  The  association  between  the  tumor 
origin of a  line and its ability to induce interferon was highly significant  (P  = 
0.00022, Fisher's exact test). None of the cell lines, including the lymphoid lines, 
spontaneously released detectable anti-viral activity when cultured alone under 
conditions comparable to those of the mixed cultures.  Moreover, the supernates 
from inducer cell lines, which included one EBV- and two SV40-producing lines, 
were unable to stimulate human lymphocytes to produce the virus inhibitor(s). 
Table  II  summarizes  the  results  of  culturing  murine  cells  from  several 
different  lines  with  human  lymphocytes  or  with  mouse  spleen  cells.  The 
supernate from BALB/c spleen cells cultured  alone usually contained  1-2 U  of 
anti-viral activity. The lines that induced anti-viral activity when cultured with 
human lymphocytes also induced such activity in mouse spleen cells, although 
the activity obtained with mouse lymphocytes was always much lower. 
Allogeneic and Syngeneic Mixed Cultures.  As a  control in each experiment, 
two allogeneic human  lymphocyte preparations were cultured  together.  When 
tested for anti-viral activity after a  24-h incubation,  the supornates from these 
cultures were always negative.  Lymphocytes from donor H. K., from whom the 
lymphoid line HK was established  by transformation of peripheral blood lym- 
phocytes  with  Epstein-Barr  virus  (EBV),  were  able  to  produce  anti-viral 
activity when mixed with autologous HK cells. When spleen cells from C57BL/6 
or BALB/c mice were cultured  with cells from lines  able to induce  interferon 
production  in  human  lymphocytes,  anti-viral  activity  was  detected  in  the 
supernate of xenogeneic, allogeneic, and syngeneic combinations (Table III). The 
anti-viralinhibitors  in the  supernates  from mixed cultures  of lymphocytes and 1302  LYMPHOCYTE  INTERFERON  INDUCTION  BY  CULTURED  CELLS 
TABLE  I 
Origin of Human Cells and Ability to Induce Anti-Viral Activity When Cultured with 
Human Lymphocytes 
Anti-viral Units 
Cell  Reference  Origin  Passages  Induced* (Mean 
_ standard error) 
Fibroblasts 
FS1 and 2  Fetal skin  14-20  <1 
Two strains  Fetal skin  35-45  <1 
Seven strains  Skin  5-20  <1 
Two strains  Brain  2-15  <1 
SV40-transformed 
Five lines  Skin  24-255  < 1 
Nine lines  Brain  4-22  <1 
$1054TR  Brain  32-37  193  -  137 
S10033WTR  Brain  8-12  125  _+  0 
Adenovirus 5-transformed 
293/31  24  <1 
NP1  24  293/31 tumor in nude mouse  <1 
Kirsten murine sarcoma virus-transformed (nonproducer) 
2-970-S  25  Osteosarcoma (TE85, C1 FS)  337  _  152 
A172-10$  Melanoma  1,562  +_  587 
Tumor-derived lines 
SW690§  Melanoma  80-90  850  _+  552 
SW691  Melanoma  80-85  6,000  _  3,000 
SW843  Melanoma  30-40  244  +_  119 
SW489  Melanoma  30-40  25  +_  0 
A375  Melanoma  76  25  __  0 
A375  Melanoma  95  194  +_  137 
Four lines  26  Colorectal carcinoma  10-95  <1 
SW620  26  Colorectal carcinoma  160-165  362  +_  137 
8W480  26  Colorectal carcinoma  105-110  125  -+ 0 
D98  (HeLa)  27  Cervical carcinoma  50-60  312  +_  165 
A673  Sarcoma  1,081  _+  649 
HT1080  28  Fibrosarcoma  110-115  < 1 
SW80  Rhabdomyosarcoma  48-50  < 1 
RDMC  29  Rhabdomyosarcoma  150-200  3,494  _+_  1,008 
TE85, C1 F5  25  Osteosarcoma  15  <1 
Lymphoid lines 
Daudi  30  Burkitt lymphoma  <1 
SB  Lymphatic leukemia  1,562  +_  823 
PGIP7  Lymphatic leukemia  1,800  -  693 
CMG  PBL-EBV  H  75  ___  28 
EB-P8  PBL-EBV  2,120  +__ 559 
HK  PBL-EBV  600  _+  0 
(B95)  (Marmoset, EBV producer)  1,800  _+  693 
* Mean of results obtained with at least four lymphocyte preparations from different donors. 
$ Cell lines with A as first letter originated in Dr. S. A. Aaronson's laboratory (National Cancer 
Institute, Viral Carcinogenesis Branch). 
§ Cell lines with SW as first letters originated in Dr.  A. Leibovitz' laboratory (Scott and White 
Clinic, Temple, Texas). 
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TABLE  II 
,Origin of Murine Cells and Ability to Induce Anti-Viral Activity When Cultured with 
Lymphocytes 
Cell line  Mouse strain  Origin  Passages 
Anti-viral units 
produced 
Human  Mouse 
lympho-  lympho- 
cytes  cytes 
BICR  Random bred albino  Brain  17-19  <1  ND* 
3T3  BALB/c  Embryo  97-101  65  ND 
NTG2  BALB/c  Embryo (3T3)  80-85  16  ND 
IT22  Random bred albino  Embryo (3T3)  47-70  <1  ND 
C1 1D  C3H/HeJ  Earle's L cells  210-213  125  16 
L-F2  C3H/HeJ  Earle's L cells  ND  16 
MG57G  C57BL/6  Methylcholanthrene-  310-325  255  ND 
induced tumor 
P815Y  DBA/2  Mastocytoma  128  32 
L-5178Y  DBA/2  Lymphoma  64  32 
F9  129/J  Embryo-derived tera-  ND  <2 
tocarcinoma 
SV40-Transformed cell lines 
C57SV  C57B1/6J  Embryo  160-170  60  8 
SV3T3  BALB/c An  Embryo  90-110  722  16 
16 lines  Various  Kidney  13-90  <1  -----2 
K129SV  129/J  Kidney  93-96  1,200  32 
KG-SV  129 G ~x-  Kidney  77-87  2,000  64 
KT6SV  CBA/H-T6J  Kidney  75-80  125  64 
K4RSV  B10.A(4R)  Kidney  70-77  600  32 
4 lines  Various  Spleen  13-80  <1  <-2 
5 lines  Various  Liver  21-30  <1  ---2 
BT6SV  CBA/H-T6J  Blood  50-60  < 1  1 
BICR-TR  Random bred albino  BICR brain  6-8  <1  ND 
Adenovirus 5-transformed cell lines 
7 Lines  Various  Kidney  17-53  <1  <2 
* ND  =  not done. 
TABLE  III 
Induction  of Anti-Viral Activity in Mixed Cultures Containing Mouse Lymphocytes and 
Xenogeneic, Allogeneic,  or Syngeneic  Cultured Cells 
Cell line  Origin 
Lymphocytes 
H-2  BALB/e  C57BL/6  (BALB/c x  B6)FI 
None  -  -  2*  <1  <1 
RDMC  Human  -  32  8  8 
SV3T3  BALB/c  d  16  4  8 
P815  DBA/2  d  64  32  16 
C57SV  C57BL/6J  b  16  4  4 
K129SV  129/J  b  32  4  8 
KT6SV  CBA/H-T6J  k  16  4  4 
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FIG,  1.  Inhibition of thymidine, Eridine, and leucine uptake in human and murine cells 
treated  with  supernates  from  mixed  cultures  of  lymphocytes  and  RDMC  cells.  The 
experimental points are expressed as percent of the  incorporation in  control cultures. 
a:[3H]thymidine incorporation in five different human cell lines (0  0) and four mouse 
cell lines (©  0). b: ©  ©,  [3H]leucine uptake; V  V, [3H]uridine uptake; []  O, 
[3H]thymidine uptake in RDMC cells. Vertical bars indicate standard deviation. 
cell lines displayed an almost complete specificity for cells of the same species of 
the lymphocytes. Supernates from xenogeneic cultures of human lymphocytes 
mixed with murine  cells or of mouse lymphocytes with human cells inhibited 
viral replication only in human and in mouse cells, respectively. 
Characterization  of  the  Viral  Inhibitor.  Supernate  from  human  mixed 
cultures was not toxic for human fibroblast cells. Pretreatment for 18 h at 37°C 
of [51Cr]labeled FS1 cells with a dilution of supernate from a mixed lymphocyte- 
RDMC  culture  containing  103  anti-viral  U  did  not  increase  the  spontaneous 
release  of 51Cr from  the  cells  (36).  The  preparations  containing  anti-viral 
activity effectively inhibited  viral  replication  at  a  dilution  at which cellular 
DNA, RNA, and protein synthesis were not affected (Fig.  1). 
The anti-viral  activity in the supernate of mixed human lymphocyte human 
cell cultures was active on FS1 cells by using different challenge viruses (NDV, 
EMC, vaccinia virus,  and influenza A  (H3N2) virus). 
The  viral  inhibitor  in the  supernate  did not inhibit  virus replication  when TRINCHIERI,  SANTOLI,  DEE,  AND  KNOWLES  1305 
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Fro. 2.  Gel filtration  on Sephadex GI00 column of  concentrated supernate from a mixed 
culture  of  human lymphocyte-RDMC cells.  Cells  were cultivated  in  the presence of  I0 ~Ci 
[~H]leucine/ml  of  medium. 30  ml of  supernate  was concentrated to  3 m] by vacuum dialysis 
and applied to the column (25 x 960 ram, 471 cm  3, void volume 160 m]).  Arrows indicate 
molecular weight markers; from left  to right:  blue dextran 2,000 (me] wt 2,000,000), 
aidolase (158,000),  ovalbumin  (45,000),  chymotrypsinogen A  (25,000),  ribonuclease A 
(13,700). The fractions were dialyzed against RMPI 1640, sterilized by filtration, and tested 
for anti-viral activity and ability to inhibit [3H]thymidine uptake in RDMC cells. 
added to the indicator cells at the same time as the virus; FS1 cells pretreated 
with the supernate  and then carefully washed were unable to replicate VSV. 
Actinomycin D (1 ftg/ml) or cycloheximide (250 ~g/ml) present during treatment 
of FS1 with dilutions of supernates containing up to 200 anti-viral U completely 
prevented the inhibition  of VSV replication. 
The viral inhibitor was completely destroyed by treatment  of diluted super- 
nate with 0.1 mg/ml of trypsin  (1 h  incubation  at 37°C).  After gel filtration  of 
concentrated supernate on a Sephade:~ G100 fine column, the anti-viral activity 
was recovered in  two peaks of apparent  mol wt of approximately  45,000  and 
25,000 daltons (Fig. 2). In some experiments,  a variable amount of activity was 
in  front  of the  albumin  peak.  Chromatography  of NDV-induced  lymphocyte 
interferon (obtained after treatment at pH 2.0) gave only one peak of anti-viral 
activity with reel wt 25,000.  When NDV interferon  was not pretreated  at pH 
2.0,  the  same  two  peaks  (45,000  and  25,000)  were  obtained.  The  anti-viral 
activity in the 25,000 peak was resistant  to treatment  at pH 2.0,  whereas the 
activity in the 45,000 peak was destroyed under the same conditions. 
The above characterization  of the viral inhibitor  in the supernates of mixed 
cultures allows their acceptance as interferons. 
Characterization  of the  Human  Lymphocyte  Population  Producing  Infer- 
feron.  Human  lymphocytes, preincubated  at 22°C  for a  period of up to 24 h, 
maintained  the ability to produce interferon  when induced  by RDMC cells in 
mixed culture or by infection with NDV. In contrast, after 17 h ofpreincubation 
at 37°C,  the lymphocytes were unable to be induced by RDMC cells,  but still 
responded to NDV infection with an anti-viral activity reduced to about 20% of 
that observed with fresh cells. 
The results of experiments with cell fractions of the lymphocyte population 
are  presented  in  Table  IV.  Depletion  of glass-adherent  cells  from  Ficoll-Hy- 1306  LYMPHOCYTE  INTERFERON  INDUCTION  BY  CULTURED  CELLS 
TABLE IV 
Ability of Human Lymphocyte  Subpopulations  to Produce Interferon  in Mixed 
L  ymphocyte-RDMC  Cultures 
Anti-viral  units 
Fraction  ANAE*  S-Ig$  E-RFC§  Fc-racll  produced 
%  %  %  % 
Exp. A Ficon-Hypaque separated  22.3  ND  ND  ND  125 
Glass nonadherent  6.7  ND  ND  ND  3,000 
Exp. B Fisell-Hypaque separated  17,9  22.7  62.9  36.6  160 
Nylon column nonadherent  1.4  2.4  86.4  20.2  640 
Nylon column adherent  30.4  35.8  24.2  66.0  10 
Exp, C Nylon column nonadheront  0.9  1.7  88.4  22.9  600 
AET-SRBC Nonrseetting  11.4  32.0  0  48.5  3,000 
AET-SRBC Rosetting  0  0  97.6  10.2  25 
Exp. D Ficoll-Hypaque separated  23.6  14.2  77.2  38.2  80 
IgG-Anti-IgG column nonadherent  9.3  0.9  89.4  9.8  <5 
IgG Column adherent  21.0  14.9  73.1  29.4  40 
* Staining for nonspacific acid eatereee, strongly positive sells (monocytas) scored (32). 
$ Positive fluorescence for surface immunoglobulin  [fluoreseein-rabbit  F(ab')~ anti-human F(ab'h] (37). 
§ Cells forming rseettes with bET-treated sheep erythrecytas (18 h incubation  at 4°C) (38). 
II Positive fluorescence for Fc-receptor with heat aggregated human IgG (39) and flureessein-labeled  anti-human IgG. 
ND, not done. 
SRBC, sheep erythrocytes. 
paque-separated lymphocytes increased  the level  of  anti-viral  activity  obtained 
by induction with RDMC  cells  (Exp A). The major population responsible  for 
interferon production in mixed cultures of lymphocytes and RDMC  cells  was 
not adherent to nylon fiber  columns, did not form rosettes  with AET-treated 
sheep erythrocytes, and was retained on an Ig-anti-IgG column.  The cell 
fractions in Exp. C  of Table IV were all incubated with erythrocytes and 
subjected  to hypo-osmotic treatment to  avoid artifactual  results  due to  different 
handling of  the subpopulations. 
Anti-Cellular  Activity. Supernates from mixed cultures  of  human lympho- 
cytes  and cells  from RDMC  or any other interferon-inducing  cell  line  inhibited 
[3H]thymidine incorporation  in human cells  from several  lines,  but not in cells 
from murine lines (Fig. I  a). [3H]leucine  and [3H]uridine incorporation were 
also  inhibited  in  human cells,  but  not  to  as  great  an  extent  as  was [3H]thymidine 
incorporation.  The supernates from unmixed cultures  of  lymphocytes or  of  cells 
from the various lines tested and the supernates  from mixed cultures of 
lymphocytes and cell  lines  unable to induce interferon  did not inhibit  incorpo- 
ration. The  activity inhibiting thymidine  incorporation and the anti-viral 
activity  were significantly  correlated  in 15 supernates from mixed cultures  of 
lymphocytes from different  donors and RDMC  cells  (r = 0.865,  P < 0.001,  Fig. 
5). About 500 anti-viral  U were required to inhibit  50% uptake in RDMC  cells 
(Figs. i  b and 3). In gel  filtration  experiments the activity  inhibiting  thymidine 
incorporation  was eluted in the same two peaks of  the anti-viral  activity. 
Inhibition of Cell Growth.  Supernates from mixed cultures of lymphocytes 
and cells from RDMC or other interferon-inducing lines were able to inhibit cell 
growth in different human cell lines (Fig. 4). This effect was detected only when 
supernate was used in concentrations containing more than 500  anti-viral U. 
The supernate from lymphocytes cultured alone or from RDMC cells cultured 
alone had no significant effect (Fig. 4). TRINCHIERI,  SANTOLI,  DEE,  AND  KNOWLES  1307 
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Discussion 
A  virus  inhibitor(s)  is  released  in  the  supernate  of  mixed  cultures  of 
lymphocytes and certain tumor-derived and virus-transformed cell lines after a 
few hours of incubation (23). The species preference of the inhibitor produced in 
the xenogeneic mixed cultures  identifies  the lymphocytes  as the producers of 
the  inhibitor.  The  viral  inhibitor(s)  from  human  mixed  cultures  meets  the 1308  LYMPHOCYTE  INTERFERON  INDUCTION  BY  CULTURED  CELLS 
criteria  established  by Lockart  (40)  for  acceptance  of a  viral  inhibitor  as an 
interferon:  (a)  it  is  a  protein  that  is  readily  destroyed  by  incubation  with 
trypsin;  (b)  it does not inhibit  viral  replication  through  a  toxic effect on the 
cells; (c) it is active against all viruses tested; (d) it does not directly inactivate 
the virus; instead it induces an anti-viral  status in the cells that persists when 
the inhibitor is removed from the medium; synthesis by the cells of both RNA 
and protein are required for induction of the anti-viral  status.  In addition,  the 
viral inhibitor shows other properties that are common to most interferons: it is 
more  active in  homologous than  heterologous cells; it  is not released sponta- 
neously  but  only  in  the  presence  of the  inducer  cell  line;  one  of the  two 
molecular populations identified by gel filtration is stable at pH 2.0. 
The  gel filtration  experiments  show that  at  least  two molecular species of 
interferon  are  present  in  the  supernate  of the  mixed  cultures.  The  viral 
inhibitor which elutes in a peak corresponding to a mol wt approximately 25,000 
represents the majority of the activity. This interferon is stable at pH 2.0, and is 
probably corresponding to the type I  interferon  of Youngner and  Salvin  (41). 
Type I interferon in the mouse is produced by cells other than T cells and can be 
induced by viruses and by B-cell stimulants  (41, 42). In humans,  NDV-induced 
leukocyte interferon  (43,  and our results)  also has a  mol wt of approximately 
25,000.  The viral inhibitor in the supernate of mixed cultures, which is eluted 
with a peak of approximately 45,000, is unstable at pH 2.0 and shares most of the 
characteristics  of the interferon designed as type II (41) or immune  (44) inter- 
feron. In the mouse, this type of interferon is considered to be a product of T cells 
activated mainly by antigenic or mitogenic stimulation  (42,  44).  However, we 
have  found  some  anti-viral  activity  in  a  peak  corresponding  to  a  mol  wt of 
45,000  after  gel  filtration  of NDV-induced  interferon  that  had  not been  pre- 
treated at pH 2.0. We have also found the presence of a variable amount of anti- 
viral  activity eluting  in  front of the  albumin  peak  possibly due to molecules 
of interferons that bind to albumin or other proteins (45). 
Cell separation experiments have been performed to identify the population 
of human peripheral  blood lymphocytes necessary for interferon production in 
the mixed cultures.  Monocytes are not only unnecessary for interferon produc- 
tion in mixed cultures but also have an inhibitory effect. Depletion of B cells 
(surface immunoglobulin-bearing cells) and monocytes by incubation on nylon 
fiber columns increased interferon production by the eluted cell population. The 
B-cell-enriched  populations  recovered  from  the  columns  produced  very little 
interferon.  On the other hand,  lymphocytes depleted of both surface immuno- 
globulin-bearing cells and Fc-receptor-bearing cells (on IgG-anti-IgG columns) 
were capable of producing  only minimal  amounts  of interferon  in the  mixed 
culture experiments. These data suggest that the major effector cell population 
is  composed of lymphocytes  without  surface  immunoglobulins  but  with  Fc- 
receptors.  To evaluate  the  role  of T  cells  in  the  production  of interferon  we 
employed AET-treated sheep erythrocytes, reported to be the most sensitive for 
rosetting  techniques  (38).  When  corrected  for  the  different  numbers  of cells 
recovered in the two populations (usually 4-10 times more cells in the rosetting 
fraction),  the data indicate that most of the interferon-producing  lymphocytes 
do not bind to AET-treated sheep erythrocytes. These results exclude a  major 
role of T cells in the production of interferon in this system. All the lymphocyte TRINCHIERI,  SANTOLI,  DEE,  AND  KNOWLES  1309 
subpopulations able to produce interferon also contained most of the activity of 
the  natural  killer  cells.  Natural  killer  cells  not  only spontaneously  interact 
with  and  lyse inducer cells  in the  mixed cultures  (46),  thus  possibly playing 
some role in the induction of interferon itself, but their cytotoxic activity is also 
strongly enhanced by the presence of interferon in the culture (36). 
In addition to the anti-viral activity, an anti-cellular activity is present in the 
supernate of mixed human lymphocyte human cell cultures. The major effect on 
cellular metabolism is inhibition of DNA synthesis,  as measured by inhibition 
of [3H]thymidine uptake. That this assay actually measures inhibition of DNA 
synthesis  and  not  an  artifactual  inhibition  of  the  uptake  of  the  labeled 
precursor,  as  observed  with  supernate  from  macrophage  and  lymphocyte 
cultures  (47,  48),  is  suggested  by these  facts:  the  inhibitory  activity  is  not 
dialyzable  and  it  inhibits  cell  proliferation.  Although  a  close  correlation 
between anti-cellular  and anti-viral  activity has been observed in the present 
experiments,  as in several other studies with virus-induced interferon  (49-52), 
no conclusion can be derived on the unsettled issue of whether or not the anti- 
cellular and the anti-viral activities in interferon preparations are mediated by 
the same molecules (45,  49-53). 
The characteristics that make certain cell lines able to induce interferon and 
the nature of the stimulus that triggers the lymphocytes are still unknown (23). 
Although the association of ability to induce interferon with transformation by 
EBV or mouse sarcoma virus or with the tumor origin of the line is statistically 
significant,  any speculation on the biological relevance of such an association 
seems premature. That stimulation by allogeneic (or heterologous) antigens are 
responsible for stimulation  may be excluded by the induction of interferon  in 
autologous or syngeneic mixed cultures, both in human and in the mouse. 
The possibility that viruses present in the cell lines are directly responsible 
for  the  induction  seems  to  be  unlikely.  The  possibility  remains  that  some 
viruses usually associated with inducer cell lines (murine sarcoma virus, EBV), 
unknown viruses or other agents derived from the original tumor or acquired in 
culture induce particular antigenic or structural surface characteristics that are 
responsible for the interaction with the lymphocytes and their stimulation. 
It is not possible to extrapolate the data obtained in vitro with cell lines to 
infer  a  stimulation  of interferon  in  vivo by  spontaneous  tumors.  Indeed,  a 
hyporeactive  factor,  which  inhibits  interferon  production,  is  present  in  the 
serum of tumor-bearing mice (54,  55).  This factor could mask a  stimulation by 
tumor cells. However, at least in the case of transplantable tumors in mice, our 
experiments and a preliminary report by others (56) show interferon induction 
by syngeneic tumor cells in vivo: because of the effect of interferon both on the 
host defense mechanisms and on the tumor cell metabolism (2) this phenomenon 
might affect the progress of the transplanted  tumor. 
Summary 
A viral inhibitor(s) is released in the supernate of mixed cultures containing 
human  or  mouse  lymphocytes and  cells  from  certain  lines.  The  inhibitor  is 
active against a variety of unrelated viruses and is a protein that is not toxic for 
cells.  It  does  not  inactivate  viruses  directly,  but  inhibits  viral  replication 
through an intracellular mechanism that involves synthesis by the cells of both 1310  LYMPHOCYTE  INTERFERON  INDUCTION  BY  CULTURED  CELLS 
RNA and protein. These characteristics identify the inhibitor as an interferon. 
The  anti-viral  activity  is  contained  in  at  least  two  molecular  species,  of 
approximately 25,000  and 45,000  daltons, respectively. In addition to the anti- 
viral  activity,  the  supernates  of the  mixed cultures display  an  anti-cellular 
activity, the inhibition of DNA synthesis and of cell multiplication. The anti- 
viral and the anti-cellular activities are positively correlated in supernates from 
various cultures and in partially purified preparations. The human cell popula- 
tion responsible for interferon production is  composed mainly of Fc-receptor 
positive, surface immunoglobulin negative, non-T-cell lymphocytes. The ability 
of certain cell lines to induce interferon seems to be preferentially associated 
with tumor origin or with in vitro transformation by certain viruses (Epstein- 
Barr virus, murine sarcoma virus). 
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